Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome

Netherlands Journal of Medicine

Volumn 71, Issue 7, 2013, Pages 342-347

  Verhave, J C ^a   Westra, D ^a   van Hamersvelt, H W ^a   van Helden, M ^a   van de Kar, N C A J ^a   Wetzels, J F M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atypical haemolytic uraemic syndrome; Eculizumab; Endothelial activation; Kidney transplantation

Indexed keywords

BASILIXIMAB; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; MONOCYTE CHEMOTACTIC PROTEIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; CASE REPORT; FEMALE; FOLLOW UP; GAIN OF FUNCTION MUTATION; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; MUTATIONAL ANALYSIS; NAUSEA; POLYMERASE CHAIN REACTION; RECURRENCE RISK; RENAL REPLACEMENT THERAPY; REVIEW; SEQUENCE ANALYSIS; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COLD ISCHEMIA; DRUG THERAPY, COMBINATION; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISONE; RECOMBINANT FUSION PROTEINS; RECURRENCE; TACROLIMUS; YOUNG ADULT;

EID: 84884181358     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Miller RB, Burke BA, Schmidt WJ, et al. Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report. Nephrol Dial Transplant. 1997;12:1425-30.
2. Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006;1:88-99.
3. Le Quintrec M, Zuber J, Moulin B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13:663-75.
4. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676-87.
5. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011;7:23-35.
6. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267-79.
7. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18:2392-400.
8. Hadaya K, Ferrari-Lacraz S, Fumeaux D, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant. 2011;11:2523-7.
9. Al-Akash SI, Almond PS, Savell VH, Jr., Gharaybeh SI, Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol. 2011;26:613-9.
10. Hodgkins KS, Bobrowski AE, Lane JC, Langman CB. Clinical grand rounds: atypical hemolytic uremic syndrome. Am J Nephrol. 2012;35:394-400.
11. Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12:3337-54.
12. Artz MA, Steenbergen EJ, Hoitsma AJ, Monnens LA, Wetzels JF. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation. 2003;76:821-6.
13. Caprioli J, Castelletti F, Bucchioni S, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet. 2003;12:3385-95.
14. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet. 2005;14:703-12.
15. Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16:555-63.
16. Licht C, Muus P, Legendre CM, et al. Abstract: [TH-PO366] Ph II Study of Eculizumab (ECU) in Patients (PTS) with Atypical Hemolytic Uremic Syndrome (aHUS) Receiving Chronic Plasma Exchange/Iinfusion (PE/PI). J Am Soc Nephrol. 2011;22: 197A (abstract).
17. Struijk GH, Bouts AH, Rijkers GT, Kuin EA, ten Berge IJ, Bemelman FJ. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant. 2013;13:819-20.
18. Sanchez-Corral P, Perez-Caballero D, Huarte O, et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet. 2002;71:1285-95.
19. Volokhina E, Westra D, Xue X, Gros P, van de Kar N, van den Heuvel L. Novel C3 mutation p. Lys65Gln in aHUS affects complement factor H binding. Pediatr Nephrol. 2012;27:1519-24.
20. Roumenina LT, Frimat M, Miller EC, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood. 2012;119:4182-91.
21. Fremeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood. 2008;112:4948-52.
22. Oyen O, Strom EH, Midtvedt K, et al. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am J Transplant. 2006;6:412-8.